-
US talking deal with 'highest people' in Cuba: Trump
-
UK ex-ambassador quits Labour over new reports of Epstein links
-
Trump says closing Kennedy Center arts complex for two years
-
Reigning world champs Tinch, Hocker among Millrose winners
-
Venezuelan activist ends '1,675 days' of suffering in prison
-
Real Madrid scrape win over Rayo, Athletic claim derby draw
-
PSG beat Strasbourg after Hakimi red to retake top spot in Ligue 1
-
NFL Cardinals hire Rams' assistant LaFleur as head coach
-
Arsenal scoop $2m prize for winning FIFA Women's Champions Cup
-
Atletico agree deal to sign Lookman from Atalanta
-
Real Madrid's Bellingham set for month out with hamstring injury
-
Man City won't surrender in title race: Guardiola
-
Korda captures weather-shortened LPGA season opener
-
Czechs rally to back president locking horns with government
-
Prominent Venezuelan activist released after over four years in jail
-
Emery riled by 'unfair' VAR call as Villa's title hopes fade
-
Guirassy double helps Dortmund move six points behind Bayern
-
Nigeria's president pays tribute to Fela Kuti after Grammys Award
-
Inter eight clear after win at Cremonese marred by fans' flare flinging
-
England underline World Cup
credentials with series win over Sri Lanka
-
Guirassy brace helps Dortmund move six behind Bayern
-
Man City held by Solanke stunner, Sesko delivers 'best feeling' for Man Utd
-
'Send Help' debuts atop N.America box office
-
Ukraine war talks delayed to Wednesday, says Zelensky
-
Iguanas fall from trees in Florida as icy weather bites southern US
-
Carrick revels in 'best feeling' after Man Utd leave it late
-
Olympic chiefs admit 'still work to do' on main ice hockey venue
-
Pope says Winter Olympics 'rekindle hope' for world peace
-
Last-gasp Demirovic strike sends Stuttgart fourth
-
Sesko strikes to rescue Man Utd, Villa beaten by Brentford
-
'At least 200' feared dead in DR Congo landslide: government
-
Coventry says 'sad' about ICE, Wasserman 'distractions' before Olympics
-
In-form Lyon make it 10 wins in a row
-
Man Utd strike late as Carrick extends perfect start in Fulham thriller
-
Van der Poel romps to record eighth cyclo-cross world title
-
Mbappe penalty earns Real Madrid late win over nine-man Rayo
-
Resurgent Pakistan seal T20 sweep of Australia
-
Fiji top sevens standings after comeback win in Singapore
-
Alcaraz sweeps past Djokovic to win 'dream' Australian Open
-
Death toll from Swiss New Year bar fire rises to 41
-
Alcaraz says Nadal inspired him to 'special' Australian Open title
-
Pakistan seeks out perpetrators after deadly separatist attacks
-
Ukraine war talks delayed to Wednesday, Zelensky says
-
Djokovic says 'been a great ride' after Melbourne final loss
-
Von Allmen storms to downhill win in final Olympic tune-up
-
Carlos Alcaraz: tennis history-maker with shades of Federer
-
Alcaraz sweeps past Djokovic to win maiden Australian Open title
-
Israel says partially reopening Gaza's Rafah crossing
-
French IT giant Capgemini to sell US subsidiary after row over ICE links
-
Iran's Khamenei likens protests to 'coup', warns of regional war
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
B.Torres--AT